Abstract:Recent studies in patients with psychotic disorders or prolactinomas suggest that increased prolactin levels may have negative effects on cognition. Most previous studies including patients with psychotic disorders are cross-sectional, and longitudinal studies are lacking. We aimed to conduct an observational, prospective study to explore whether prolactin levels during the first year of treatment are associated with changes in cognitive tasks. Our hypothesis would be that those patients with increased prolactin levels would show a poorer cognitive outcome than those patients with lower prolactin levels. We studied 60 patients (24.5 ± 6.8 years; 36% women) with a first episode psychosis (FEP) attending the Early Psychosis Programme from two institutions (Parc Taulí Hospital Universitari, Sabadell, Spain; Hospital Universitari Institut Pere Mata). Ethical approval was obtained from the local Ethics Committees of both institutions. Clinical diagnoses for a FEP were generated with the OPCRIT checklist v.4.0 after a semistructured interview by a psychiatrist. The MATRICS Consensus Cognitive Battery (MCCB) was administered to explore neuropsychological functioning at two-time points (baseline, 1 year). The MCCB contains 10 tests to measure cognitive performance in 7 cognitive domains. Three fasting blood samples (baseline, 6 months, 12 months) were obtained in the morning between 8:30 h and 9:30 h in resting conditions, to determine unstimulated plasma prolactin. Serum prolactin levels were determined with immunoassays standardized against the 3rd International Reference Standard 84/500. Statistical analyses were performed with SPSS version 21.0. As prolactin levels might be increased by stress, particularly at the onset of the FEP, we calculated mean prolactin levels over the follow-up period taking into account prolactin values at 6 and 12 months. A general linear model for repeated measures was performed in order to test whether longitudinal changes in cognitive tasks differed by mean prolactin levels. All analyses were adjusted for gender. A p value < 0.05 (two-tailed) was considered to be significant. For descriptive purposes, patients in the fourth quartile for serum prolactin (>47.8 ng/ml for men; >54.3 ng/ml for women) where compared with those with lower prolactin levels. Patients improved in all 10 MCCB cognitive tasks one year later (p<0.05 for all tasks). When exploring the interaction between time x prolactin in the GLM analyses, significant interactions were found for three cognitive tasks related with processing speed (BACS-SC [F= 5.9, p= 0.018]; Fluency [F= 5.6, p= 0.022]) and reasoning and problem solving (NAB mazes [F= 4.8, p= 0.033]). Percent change over the follow-up period in these cognitive tasks was greater for patients with lower prolactin levels, when compared to those in the highest quartile: BACS-SC (11.8% vs 0.6%), Fluency (8.5% vs -7.4%) and NAB mazes (10.7% vs -1.1%). Our study is in accordance with previous cross-sectional studies reporting a negative effect of prolactin levels on cognition and adds new information with a prospective design. A limitation of our study is that patients were treated with different antipsychotics based on the clinical routine practice. Antipsychotic-induced hyperprolactinaemia, which is caused by tuberoinfundibular blockade of D2 receptors, may be reflecting the blockade of D2 receptors in other dopaminergic pathways (striatum and mesocortical pathways) that may also affect cognitive abilities. Further clinical trials are needed to reduce the heterogeneity of the treatment effects and to confirm the potential negative effects of prolactin on cognitive abilities.

The relationship between serum prolactin levels and cognitive function in drug-naïve schizophrenia patients: a cross-sectional study

The Association Between Prolactin Levels and Cognitive Function in Female Patients With Severe Mental Disorders

F87. SERUM PROLACTIN LEVELS AND COGNITIVE OUTCOME IN FIRST EPISODE PSYCHOSIS: A PROSPECTIVE 1-YEAR FOLLOW-UP STUDY

Sex differences in prolactin levels and clinical outcomes in patients with a first psychotic episode

Sex differences in the association between serum BDNF and cognitive impairment in schizophrenia patients using various antipsychotics

The Effects of Antipsychotics on Serum Prolactin in the First-Episode Schizophrenia Patients

Correlations of cognitive function with serum levels of homocysteine, sex hormone binding globulin, and leptin in patients with schizophrenia

Sex differences between serum total bilirubin levels and cognition in patients with schizophrenia

Interrelationships between sex hormones, brain-derived neurotrophic factor, and cognitive impairment in male patients with schizophrenia and receiving chronic antipsychotic treatment

Serum total cholesterol levels associated with immediate memory performance in patients with chronic schizophrenia

Relationships between serum brain-derived neurotrophic factor, plasma catecholamine metabolites, cytokines, cognitive function and clinical symptoms in Japanese patients with chronic schizophrenia treated with atypical antipsychotic monotherapy

Prolactin Levels Influenced By Antipsychotic Drugs In Schizophrenia: A Systematic Review And Network Meta-Analysis

Prolactin Serum Levels in First-Episode Neuroleptic-Naive Patients with Pituitary Microadenoma and Comorbid Psychosis

Relationship of Serum Testosterone Levels with Cognitive Function in Chronic Antipsychotic-Treated Male Patients with Schizophrenia.

A study on the correlations of PRL levels with anxiety, depression, sleep, and self-efficacy in patients with prolactinoma

Correlations between Immunoinflammatory Factor Levels and Cognitive Functions and Brain Structural Magnetic Resonance Imaging Features among Patients with Primary Schizophrenia

Relationship between serum levels of BDNF,IL-6 and Hcy with cognitive function impairment in patients with first episode schizophrenia

Investigating the relationship between cognitive impairment and brain white matter tracts using diffusion tensor imaging in patients with prolactinoma

Association between serum insulin-like growth factor 1 levels and the improvements of cognitive impairments in a subgroup of schizophrenia: Preliminary findings

Hormone Levels Are Related to Altered Functional Connectivity in Prolactinomas